Immunocore appoints Mohammed DarImmunocore has appointed Dr Mohammed Dar as Head of Clinical Development and Chief Medical Officer. Mohammed Dar will lead the continued clinical development of tebentafusp(IMCgp100) and other key programmes … more ➔
Dr Stuart Quin appointed as CEO of Medica...Medica Group Plc (LSE:MGP) announces that Dr Stuart Quin has been appointed as Chief Executive Officer. Dr Quin will join Medica and its Board of Directors on 1 September 2019. John Graham will remain … more ➔
Immunic appoints Tamara A. Seymour as Inte... Immunic, Inc., a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today … more ➔
Jo Easton Appointed Non-Executive Director Medica Group Plc (LSE:MGP) announces that Jo Easton has been appointed to the Groups Board of Directors as a non-executive director. On joining the Board, Jo will be appointed to the audit, nomination … more ➔
IGEM Therapeutics appoints Dr David Chiswe... IGEM Therapeutics, an immuno-oncology company developing novel immunoglobulin E (IgE) antibodies to treat cancer, announces that Dr David Chiswell will be joining IGEM as a Non-Executive … more ➔
Metrion Biosciences appoints Dr Andrew Sou... Metrion Biosciences today announced the appointment of Dr Andrew Southan as Chief Executive Officer, with immediate effect. Dr Southan was previously the Companys Chief Operating Officer. more ➔
Theodora Harold appointed CEO of Crescendo... Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T-cell enhancing therapeutics, today announces that Theodora Harold, the current CFO, will be appointed as CEO. She will be … more ➔
Ergomed appoints Roy Ovel Ergomed plc, a company focused on providing specialised services to the pharmaceutical industry, today announces the appointment of Roy Ovel as Chief Commercial Officer with immediate effect. more ➔
Neophore appoints Dr John Haurum Neophore Limited, a cancer immuno-oncology company, today announces the appointment of Dr John Haurum as Non-Executive Director with immediate effect. more ➔
Mats Blom joins Modus as CFO Modus Therapeutics AB, a company developing innovative treatments for patients with high unmet medical needs and a focus on sickle cell disease (SCD), announces the appointment of Mats Blom as Chief … more ➔